It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > Myelofibrosis > Mechanism of Action

JAKAVI is a potent JAK1 and JAK2 inhibitor

  • JAKAVI acts on both JAK1 and JAK2 to inhibit overactive JAK/STAT signalling in MF[1]
  • JAKAVI binds to the kinase domain of JAK1 and JAK2 and inhibits JAK1 and JAK2 signalling regardless of the JAK2V617F mutation status[1]
  • JAKAVI inhibits JAK stimulation of STAT and downstream effects on cellular proliferation[1]

Hydroxyurea is a cytoreductive therapy and does not alter the natural history of the disease[2]


 

References

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; August 2021.

  2. Mughal T, Vaddi K, Sarlis NJ, Verstovsek S. Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes. Int J Gen Med. 2014;7:89-101.